Compounded Tirzepatide Injection

Compounded GLP-1. Weekly subcutaneous self-injection

Dual GIP and GLP-1 receptor agonist. Combining both incretins drives greater average weight loss in trials than single-mechanism GLP-1s.

Dosing: Set by your prescriber and adjusted over time based on how you respond.

Best for: Patients with more weight to lose or those plateaued on semaglutide.

Key points

• Dual GIP + GLP-1 mechanism; contains tirzepatide, not FDA-approved and not an approved generic of branded tirzepatide products
• Highest average weight loss of any GLP-1 in clinical trials
• Weekly injection with a titration plan tailored to the patient
• Compounded by a US 503A pharmacy when clinically appropriate

Considerations

• Prescription-only, licensed clinician review required
• GI side effects (nausea, constipation) most common during dose escalation
• Same contraindications as semaglutide-class medications

Prescription treatment requires an online consultation with a licensed HELiXVi clinician. Individual results vary.

Start your free consultation right now

No clinic visit. Licensed US clinicians. Dispatched within 24 hours of your consultation and payment.

See the full weight loss program